Form 4: Bioventus Director John Bartholdson Reports RSU Activity

Director John Bartholdson exercised restricted stock units and received a new grant of equity in Bioventus Inc.

Summary

• Director John Bartholdson acquired 32,282 shares of Class A Common Stock through the vesting of restricted stock units (RSUs) on June 2, 2026.
• Following the transaction, the director holds 111,902 shares directly and maintains indirect beneficial ownership of 6,939,357 shares through various Juniper entities.
• A new grant of 25,146 RSUs was awarded to the director on June 3, 2026, scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine equity compensation and maintenance of existing ownership stakes.

Positives

• Director maintains significant alignment with shareholders through substantial direct and indirect equity holdings.

Negatives

• None noted.

Risks

• Vesting of new RSU grants is contingent upon the director continuing service on the Board of Directors.

Future Outlook

The director received a new grant of 25,146 RSUs which will vest on the earlier of the day before the next annual meeting or the first anniversary of the grant, provided the director remains in service.

Industry Context

StockSavvy.ai notes that this filing represents standard equity compensation and director-level ownership adjustments, which are common in the medical device sector to ensure board alignment with long-term corporate performance.

Comparison to Industry Standards

• The director's ownership structure is consistent with standard practices for board members representing significant institutional investment firms.
• Equity compensation levels are in line with typical non-employee director compensation packages for mid-cap medical technology companies.

Related Party Transactions

• The reporting person is a managing member of Juniper Investment Company and associated entities, which hold 6,939,357 shares of the issuer.

Stakeholder Impact

• No material impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 25,146 RSUs granted on June 3, 2026, subject to continued board service.

Key Dates

Keywords

Bioventus, BVS, Insider Trading, Form 4, Equity Compensation, Director Ownership